AI's role in strategic pharma decision-making: New industry insights
This research brief examines pharmaceutical leaders' risk assessment and strategic decision-making, emphasizing artificial intelligence (AI). Surveying over 100 management professionals, findings reveal:
- Main challenges are data availability, subjectivity, and non-standardized risk assessment processes
- While traditional methods like historical analysis are common, AI is underused
- Decision-makers prioritize outcomes data over KOL assessments
- A mere 25% employ AI in portfolio decisions, suggesting a significant opportunity
The study suggests AI, like Intelligencia's Portfolio Optimizer, could enhance objectivity in pharma risk assessment. The full brief offers more insights.